Literature DB >> 25359361

Re-inventing clinical trials through TransCelerate.

Dalvir Gill1.   

Abstract

TransCelerate BioPharma was formed in 2012 as a non-profit organization with a mission to collaborate across the biopharmaceutical research and development community to identify, prioritize, design and facilitate the implementation of solutions to drive efficient, effective and high-quality delivery of new medicines.

Mesh：

Year:  2014        PMID： 25359361     DOI： 10.1038/nrd4437

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  5 in total

Review 1.  Good Clinical Practice Guidance and Pragmatic Clinical Trials: Balancing the Best of Both Worlds.

Authors:  Robert J Mentz; Adrian F Hernandez; Lisa G Berdan; Tyrus Rorick; Emily C O'Brien; Jenny C Ibarra; Lesley H Curtis; Eric D Peterson
Journal:  Circulation       Date:  2016-03-01       Impact factor: 29.690

Review 2.  Opportunities and Challenges for Drug Development: Public-Private Partnerships, Adaptive Designs and Big Data.

Authors:  Oktay Yildirim; Matthias Gottwald; Peter Schüler; Martin C Michel
Journal:  Front Pharmacol       Date:  2016-12-06       Impact factor: 5.810

Review 3.  Adaptation through Collaboration: Developing Novel Platforms to Advance the Delivery of Advanced Therapies to Patients.

Authors:  Magdalini Papadaki
Journal:  Front Med (Lausanne)       Date:  2017-05-29

4.  A new risk and issue management system to improve productivity, quality, and compliance in clinical trials.

Authors:  Joseph Ciervo; Shih Chuan Shen; Kristin Stallcup; Abraham Thomas; Michael A Farnum; Victor S Lobanov; Dimitris K Agrafiotis
Journal:  JAMIA Open       Date:  2019-03-19

5.  Regional variations in adverse event reporting rates and ACR responses in placebo/standard-of-care arms of rheumatoid arthritis trials.

Authors:  Daniel Keebler; Edmond Teng; Jenny Chia; Joshua Galanter; Jodie Peake; Katie Tuckwell
Journal:  Rheumatology (Oxford)       Date:  2020-10-01       Impact factor: 7.580
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.